权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CLINICAL TRIAL: ANTI-LEUKOTRIENE THERAPY FOR COPD EXACERBATIONS

临床试验：抗白三烯疗法治疗慢性阻塞性肺病恶化

基本信息

批准号：
7951176
负责人：
STEVEN M SCHARF
金额：
$ 1.14万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-03-01 至 2010-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7951176
关键词：
Accounting Acute Adrenal Cortex Hormones Antibiotics Arachidonate 5-Lipoxygenase Asthma Bronchodilator Agents Caring Cessation of life Charge Chronic Obstructive Airway Disease Clinical Research Clinical Trials Computer Retrieval of Information on Scientific Projects Database Cost Savings Data Drops Funding Grant Health Care Costs Hospitalization Hospitals Inflammation Mediators Inpatients Institution Length of Stay Leukotriene B4 Leukotriene E4 Leukotrienes Lipoxygenase Inhibitors Morbidity - disease rate Motivation Oral Patients Plasma Play Pulmonary Function Test/Forced Expiratory Volume 1 Research Research Personnel Resources Risk Factors Role Severities Source Sputum United States Agency for Healthcare Research and Quality United States National Institutes of Health Zileuton base mortality neutrophil novel therapeutic intervention prednisolone safety testing treatment as usual

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Exacerbations of chronic obstructive pulmonary disease impose a considerable burden with regard to morbidity, mortality, and health care cost. In the year 2000, COPD exacerbations were responsible for 726,000 hospitalizations, and 119,000 deaths in the US. Based on data from the Agency for Healthcare Research and Quality, patients admitted to US hospitals for COPD in 2002 had a mean length of stay of 5.1 days and accounted for $15,400 in charges. Current management of COPD exacerbations includes bronchodilators, corticosteroids, and antibiotics. Because leukotrienes may play an important role in COPD exacerbations, we propose to study whether anti-leukotriene therapy provides additional benefit to usual care in the management of COPD exacerbations requiring inpatient care. The rationale for anti-leukotriene therapy in acute exacerbations of COPD is based on studies of mediators of inflammation in COPD, on clinical trials of anti-leukotriene therapy in COPD, and on a clinical trial of anti-leukotriene therapy in exacerbations of asthma. The motivation for identification of a novel therapeutic approach to COPD exacerbations is that a reduction in hospital length of stay should result in significant cost savings in the management of this common condition. Clinical studies of the role of leukotrienes in COPD exacerbations indicate that leukotriene levels are elevated in acute exacerbations of COPD, that these elevations are associated with the severity of exacerbation, that levels drop with treatment of the exacerbation and that leukotriene B4 (LTB4)contributes significantly to the neutrophil chemotactic activity of sputum. Shindo et al. demonstrated that mean plasma leukotriene E4 (LTE4) levels in patients with COPD are elevated during acute exacerbation before treatment. They also found that LTE4 levels correlated with PaO2 and FEV1 in patients during acute exacerbation before prednisolone treatment, suggesting that elevated LTE4 levels are a risk factor for more severe exacerbations. The purpose of this study is to test the safety and efficacy of oral zileuton (a 5-lipoxygenase inhibitor) in addition to usual care for treatment of acute exacerbations of COPD requiring inpatient care.

这个子项目是众多研究子项目之一